Mallinckrodt and Endo Announce $6.7 Billion Merger Agreement

Pharmaceutical companies Mallinckrodt and Endo have agreed to merge in a deal valued at $6.7 billion, combining cash and stock transactions. The merger will integrate the branded product portfolios of both firms while establishing a new focus on rare and orphan diseases. As part of the agreement, their generic medicines division will be spun off into a separate entity.

The companies stated that the merger aims to create a robust foundation for addressing rare medical conditions, leveraging their combined expertise and resources. Both Mallinckrodt and Endo currently market branded pharmaceutical products, which will remain central to the merged business’s operations. Meanwhile, the decision to separate generic medicines into an independent company reflects a strategic move to streamline operations and focus on specialized areas of healthcare innovation.

Date: March 13, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Sanofi’s Head of Rare Diseases Discusses Future Developments on Rare Disease Day 2025 Breakthrough AI Tool Identifies Life-Saving Medication for Rare Disease Patient CHMP Announces Key Approvals and Updates in February 2025 Meeting AI-Powered Infant Wearable Tracks Early Motor Development at Home

Author

Mark Chiang